OncLive TV

Nilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.

Sebastian C. Schmid, MD, discusses the use of preoperative radiation therapy plus immunotherapy in urothelial carcinoma.

Stephen M. Ansell, MD, PhD, discusses the investigation of loncastuximab tesirine in the phase 2 LOTIS-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

Barry Paul, MD, discusses the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome following CAR T-cell therapy in cancer care.

Aaron T. Gerds, MD, MS, discusses the phase 3 VERIFY trial examining rusfertide in patients with polycythemia vera.

Sanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.

Pedro C. Barata, MD, MSc, discusses the evolving treatment landscape of urothelial cancer.

Srdan Verstovsek, MD, PhD, discusses the potential for rusfertide in polycythemia vera.

Nicolas Girard, MD, PhD, discusses the investigation of lurbinectedin in small cell lung cancer.

John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.

Jeanny B. Aragon-Ching, MD, FACP, discusses the evolving standard of care based on findings from the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Victor M. Orellana-Noia, MD, discusses the patient population of the phase 3 POLARIX trial in diffuse large B-cell lymphoma.

Helen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.

Jeanny B. Aragon-Ching, MD, FACP, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Matthew J. Matasar, MD, discusses the unmet needs remaining in diffuse large B-cell lymphoma.

Adana A.M. Llanos, PhD, MPH, discusses disparities in genetic research in cancer care.

Matthew P. Goetz, MD, discusses the progression-free survival benefit derived with lasofoxifene in patients with ESR1-mutated, ER-positive/ HER2-negative metastatic breast cancer.

Senthil Damodaran, MD, PhD, discusses data from the phase 2 ELAINE-2 trial examining the combination of lasofoxifene and abemaciclib in patients with ESR1-mutated, estrogen receptor–positive/HER2-negative metastatic breast cancer.

Martin E. Gutierrez, MD, discusses the investigation of MK-0482 in advanced solid tumors. 

Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.

Madhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.

Andre H. Goy, MD, discusses updates in precision medicine.

Andrew Ip, MD, discusses carboplatin, pemetrexed, and pembrolizumab as first-line therapy in recurrent/metastatic non–small cell lung cancer.

James K. McCloskey, MD, discusses the efficacy of CPX-351 in FLT3-mutated acute myeloid leukemia.

Srdan Verstovsek, MD, PhD, discusses the FDA approval of pemigatinib, an FGFR1 inhibitor, in patients with myeloid neoplasms with an FGFR1 rearrangement.

Shanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.

Paul A. DiSilvestro, MD, discusses the 7-year follow up data of maintenance olaparib in advanced ovarian cancer.

John H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.

Sapna Patel, BA, MD, discusses the neoadjuvant administration of pembrolizumab in advanced melanoma.